利格列汀联合长效胰岛素治疗2型糖尿病的疗效观察

Efficacy of ligliptin combined with long-acting insulin in the treatment of type 2 diabetes mellitus

目的:探讨利格列汀联合长效胰岛素在2型糖尿病患者治疗中的疗效.方法:60例治疗后HBA1c>9%的2型糖尿病患者,随机分两组,A组:利格列汀+二甲双胍+甘精胰岛素.B组:赖脯胰岛素+二甲双胍+甘精胰岛素.观察治疗效果.结果:治疗16周后两组治疗前后HBA1c、FBG、PBG均明显下降(P<0.01).两组之间HBA1c、FBG、PBG降幅相似,差异无统计学意义(P>0.05),低血糖发生率、体质量增加与每日胰岛素使用总量A组均低于B组,差异有统计学意义(P<0.01),结论:利格列汀联合二甲双胍,甘精胰岛素治疗未达标的2型糖尿病患者,血糖控制良好,低血糖风险小,胰岛素用量少,体质量无明显增加.

Objective: To investigate the efficacy of ligliptin combined with long-acting insulin in the treatment of type 2 diabetes mellitus. Methods: 60 patients with type 2 diabetes mellitus (HBA1c> 9%) were randomly divided into two groups. Group A: ligliptin + metformin + insulin glargine. Group B: Insulin Laipu + Metformin + Insulin Glargine. To observe the therapeutic effect. Results: After 16 weeks of treatment, HBA1c, FBG and PBG decreased significantly in both groups before and after treatment (P< 0.01). There was no significant difference between the two groups in the decrease of HBA1c, FBG and PBG(P> 0.05). The incidence of hypoglycemia, weight gain and total daily insulin use in group A were lower than those in group B. The difference was significant (P< 0.01). Conclusion: Ligliptin combined with metformin and insulin glargine in the treatment of type 2 diabetes patients who did not meet the standard. Good blood sugar control, low risk of hypoglycemia, low insulin dosage, no significant increase in body weight.